...
首页> 外文期刊>International journal of antimicrobial agents >Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections
【24h】

Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections

机译:耐甲氧西林金黄色葡萄球菌血液感染的多方面抗生素治疗分析

获取原文
获取原文并翻译 | 示例
           

摘要

Given the overall prevalence and poor prognosis of Staphylococcus aureus bloodstream infections (BSIs), the study of treatment strategies to improve patient outcomes is important. The aim of this study was to conduct a multifaceted antibiotic treatment analysis of methicillin-sensitive S. aureus (MSSA) BSI and to characterise optimal early antibiotic therapy (within the first 7 days of drawing the index blood culture) for this serious infection. Antibiotic selection was categorised as optimal targeted (intravenous cloxacillin or cefazolin), optimal broad (piperacillin/tazobactam or meropenem), adequate (vancomycin) or inadequate (other antibiotics or oral therapy). A TSE (timing, selection, exposure) score was developed to comprehensively characterise early antibiotic therapy, where higher points corresponded to prompt initiation, optimal antibiotic selection and longer exposure (duration). Amongst 71 cases of complicated MSSA-BSI, end-of-treatment (EOT) response (i.e. clinical cure) was improved when at least adequate antibiotic therapy was initiated within 24 h [71.7% (33/46) vs. 48.0% (12/25); P = 0.047]. Clinical cure was also more likely when therapy included = 4 days of optimal targeted antibiotics within the first 7 days [74.4% (29/39) vs. 50.0% (16/32); P = 0.03]. The TSE score was an informative index of early antibiotic therapy, with EOT cure documented in 72.0% (36/50) compared with 42.9% (9/21) of cases with scores above and below 15.2, respectively (P = 0.02). In multivariable analysis, lower Charlson comorbidity index, presence of BSI on admission, and optimising early antibiotic therapy, as described above, were associated with clinical cure in patients with MSSA-BSI. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
机译:考虑到金黄色葡萄球菌血流感染(BSI)的总体患病率和预后不良,研究改善患者预后的治疗策略非常重要。这项研究的目的是对甲氧西林敏感的金黄色葡萄球菌(MSSA)BSI进行多方面的抗生素治疗分析,并为这种严重感染确定最佳的早期抗生素治疗(在抽取血培养指数的前7天内)。抗生素选择分为最佳靶向药物(静脉注射氯西林或头孢唑林),最佳抗生素选择范围(哌拉西林/他唑巴坦或美罗培南),适当药物(万古霉素)或不足药物(其他抗生素或口服疗法)。制定了TSE(时间,选择,暴露)评分以全面表征早期抗生素治疗的特征,其中较高的分数对应于迅速开始,最佳的抗生素选择和更长的暴露(持续时间)。在71例复杂的MSSA-BSI病例中,至少在24小时内开始适当的抗生素治疗后,治疗结束(EOT)反应(即临床治愈)有所改善[71.7%(33/46)对48.0%(12) / 25); P = 0.047]。当治疗包括前7天内4天内最佳靶向抗生素治疗时,临床治愈的可能性也更高[74.4%(29/39)对50.0%(16/32); P = 0.03]。 TSE评分是早期抗生素治疗的信息指标,EOT治愈率达到72.0%(36/50),而得分分别高于和低于15.2的病例为42.9%(9/21)(P = 0.02)。在多变量分析中,如上所述,较低的查尔森合并症指数,入院时存在BSI以及优化早期抗生素治疗与MSSA-BSI患者的临床治愈率相关。 (C)2016 Elsevier B.V.和国际化学疗法学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号